NW-301V clinical trials
Also written NW-301V.
How each study uses NW-301V is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the NW-301V studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- NW-301V
- 5
Studies by the year they started
5 studies that test it; most in 2024 (3)
| Year | Studies |
|---|---|
| 2024 | 3 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 4
TingBo Liang (1) · Neowise Biotechnology (1) · Peking University (1) · Ting Deng (1) · Tao Zhang (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test NW-301V.
- Dec 2026NW-301 TCR-T in Patients With Advanced Solid TumorPhase 1 · Peking University
Studies
Open first, then newest update. How each study uses NW-301V is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Phase 1 Study of NW-301V TCR-T Cells in Advanced Solid Tumors With KRAS G12V MutationNot yet recruitingPhase 1Neowise BiotechnologyNCT07875920Written as NW-301V
- T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid TumorRecruitingPhase 1Ting DengNCT06484790Written as NW-301V
- T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid TumorRecruitingPhase 1Tao ZhangNCT06484556Written as NW-301V
- NW-301 TCR-T in Patients With Advanced Solid TumorNot yet recruitingPhase 1Peking UniversityNCT06956261Written as NW-301V
- T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid TumorActive, not recruitingPhase 1TingBo LiangNCT06478251Written as NW-301V